1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. DIVI'S LABORATORIES LTD.
Divi's Laboratories Ltd.
NSE: DIVISLAB | BSE: 532488

Divi's Laboratories Live Share Price Today, Share Analysis and Chart

Expensive Star
BasketIn 3 Starfolio Baskets
aboutDivi's Laboratories Ltd. is a leading Indian pharmaceutical company primarily engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical ingredients. It holds a significant global position as one of the t... Read More
US FDA Inspections
Ask AI about Divi's Laboratories
9780.00116.00(1.20%)

New 52W High today

1.1M
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Divi's Laboratories is on 07 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
70.2 / 100
Expensive StarThese stocks are bullish, strong in quality and technicals, but expensive in valuation. Investors need to be cautiousView SimilarEmbed DVM
Analyst Price Target
-

36

S

7

W

8

O

0

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

15Positive8Negative

Pass in checklist65.2%

045
55
100

PE Valuation Check

Right Now
Overvalued
-28.1%
1 Year Forward
Overvalued
-18.6%
INSIGHTDivi's Laboratories is overvalued at both current PE and future earnings estimates.

Divi's Laboratories Stock Price Analysis

Day Price Range

1.2% 1 Day return
9780 (LTP)
9,621.59,865
LowHigh

Week Price Range

9.3% 1 Week return
9780 (LTP)
8,8609,865
LowHigh

Month Price Range

3.7% 1 Month return
9780 (LTP)
8,7979,865
LowHigh

52 Week Price Range

47.0% 1 Year return
9780 (LTP)
5,647.59,865
LowHigh
View full Price History/Seasonality

Divi's Laboratories Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Divi's Laboratories's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
96.8
AVG. ESTIMATE
123.3
LOW ESTIMATE
110.5
HIGH ESTIMATE
140.8
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 27.4% in FY27

Consensus Recommendation

29 ANALYST Recommendations
HOLD

The consensus recommendation from 29 analysts for Divi's Laboratories is HOLD

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Divi's Laboratories Technical Analysis

Divi's Laboratories EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day9555.2
10 Day9420.3
12 Day9395.8
20 Day9344.8
26 Day9310.5
50 Day9074.6
100 Day8492.4
200 Day7750.1

Divi's Laboratories Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202656.4%
Week56.3%
Month63.7%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Divi's Laboratories Resistance and Support

9755.50
Pivot
First Resistance9889.5
Second Resistance9999
Third Resistance10133
First Support9646
Second Support9512
Third Support9402.5
Day RSI64.4
Day MACD85.3
Day MFI61.7
Day MACD Signal Line35

Divi's Laboratories Beta

1 Month0.6
1 Year0.6
3 Month0.9
3 Year0.6

Divi's Laboratories Price Change Analysis

↑3.7%
Over 1 Month
LowHigh
87979865
↑24.8%
Over 3 Months
LowHigh
7870.59865
↑49.7%
Over 6 Months
LowHigh
64299865
↑47.0%
Over 1 Year
LowHigh
5647.59865
All Technicals →

Divi's Laboratories Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Satchandra Kiran DiviPromoter54,000,00020.3 %
Government Of SingaporeFii7,537,1222.8 %
Sbi Mutual FundDii9,507,0423.6 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Divi's Laboratories Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GOLDMAN SACHS (SINGAPORE) PTE - ODIBlockSell09 Oct 20256120.5033,108NSE
GOLDMAN SACHS BANK EUROPE SE - ODIBlockPurchase09 Oct 20256120.5033,108NSE
THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828BlockSell14 Jul 2025683521,874NSE
THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849BlockPurchase14 Jul 2025683521,874NSE
PRAZIM TRADING AND INVESTMENT COMPANY PRIVATE LIMITEDBlockSell06 Nov 20245979.6580,324NSE
PI OPPORTUNITIES AIF V LLPBlockPurchase06 Nov 20245979.6580,324NSE
RONDURE NEW WORLD FUNDBlockSell20 Oct 20233637.7043,478BSE
NORTHERN LIGHTS FUND TRUST III RONDURE NEW WORLD FUNDBlockPurchase20 Oct 20233637.7043,478BSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell14 Nov 20223271.40209,124NSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase14 Nov 20223271.40209,124NSE
All deals
All insider trades

Divi's Laboratories Corporate Actions

Divi's Laboratories Dividend history and yield

Divi's Laboratories dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Divi's Laboratories dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
124 Jul 2026
30FINAL24 Jul 2026Equity Share
225 Jul 2025
30FINAL25 Jul 2025Equity Share
302 Aug 2024
30FINAL02 Aug 2024Equity Share
411 Aug 2023
30FINAL11 Aug 2023Equity Share
511 Aug 2022
30FINAL12 Aug 2022Equity Share

Divi's Laboratories Bonus shares

Divi's Laboratories bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
123 Sep 2015
1:126 Sep 2015
230 Jul 2009
1:101 Aug 2009

Divi's Laboratories Board Meetings

Divi's Laboratories past and upcoming board meetings.

#Ex-Date
PurposeNotes
107 Nov 2026
Quarterly Results-
201 Aug 2026
Quarterly Results-
323 May 2026
Audited Results & Dividend-
411 Feb 2026
Quarterly Results-
507 Nov 2025
Quarterly Results-

Divi's Laboratories Stock Split

Divi's Laboratories stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
103 Aug 2007
102-
All Corporate Actions

Divi's Laboratories Research Reports

Divi's Laboratories research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
103 Aug 2026Deven Choksey
Target
85218378Hold1.71%16.73%pdf
201 Aug 2026Motilal Oswal
Target
77208056Neutral-4.17%21.4%pdf
307 Jul 2026Deven Choksey
Target
71576755Accumulate5.95%44.78%pdf
427 May 2026Deven Choksey
Target
71556797.5Accumulate5.26%43.88%pdf
524 May 2026Prabhudas Lilladhar69006756.5Accumulate2.12%44.75%pdf
All Reports of Divi's

Divi's Laboratories Corporate Filings

Divi's Laboratories BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
22 Oct 2026
Divis Laboratories Ltd - 532488 - Board Meeting Intimation for Considering And Approving Unaudited Financial Results For Quarter And Half Year Ended September 30, 2026.
Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2026 ,inter alia, to consider and approve unaudited financial results for quarter and half year ended September 30, 2026.
PDF
06 Oct 2026
Divis Laboratories Ltd - 532488 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026
PDF
30 Sep 2026
Divis Laboratories Ltd - 532488 - Closure of Trading Window
Intimation of closure of Trading Window from 01.10.2026 till 48 hours of declaration of financial results for the quarter and half year ended 30.09.2026.
PDF
12 Sep 2026
Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Clippings - Special Window for transfer and dematerialisation of physical shares
PDF
10 Aug 2026
Divis Laboratories Ltd - 532488 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Submission of Scrutinizer''s report on 36th AGM resolutions.
PDF
VIEW ALL

Divi's Laboratories DocumentsAsk MarketMind AI

Divi's Laboratories Earnings Call

Divi's Laboratories earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
06 Aug 2026Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
29 May 2026Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
14 Feb 2026Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
11 Feb 2026Divi's Laboratories Results Earnings Call for Q3FY26AudioVideo
12 Nov 2025Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAi summaryLink
view all

Divi's Laboratories Annual Reports

Divi's Laboratories financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link

Divi's Laboratories Credit Ratings

Divi's Laboratories credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
04 Oct 2021care ratingsDivis Laboratories LimitedLink
25 Aug 2021care ratingsDivis Laboratories LimitedLink
27 Sep 2020care ratingsDivis Laboratories LimitedThe ratings assigned to the bank facilities of Divi's Laboratories Limited (DLL) derives strength from increased operating income coupled with healthy profitability margins during FY20 (refers to the period April 01 to March 31), comfortable capital structure as on March 31, 2020 and strong debt coverage indicators. The ratings also factor in experience of the promoters and management team, established track record in Contract Research and Manufacturing Services (CRAMS) segment with reputed clientele and strong research and development capabilities and favorable industry outlook. The ratings are,...Link
06 Jan 2019care ratingsDivis Laboratories LimitedLink

Divi's Laboratories - Company Profile

Divi's Laboratories Management Structure

Divi's Laboratories management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Kiran S DiviExecutive Director,Whole Time Director,Chief Executive Officer3484Mar 26
Mr. E.S.V.S. Rama Krishna PrasadGeneral Manager(Engineering)-Mar 26
J Srinivasa RaoGeneral Manager(Raw Materials Division)-Mar 26
B Vara PrasadGeneral Manager(Engineering)-Mar 26
Mr. N.V. AnirudhPresident(Nutraceuticals)-Mar 26
Satish ChoudhuryCompany Secretary,Compliance Officer-Mar 26
Mr. Ravi SureshDeputy General Manager(Engineering)-Mar 26
Mr. Manoranjan JastiChief Information Officer-Mar 26
Mr. S. BalajiGeneral Manager-Mar 26
Mr. V. Naga SekharGeneral Manager(Engineering)-Mar 26
Mr. Satya Prakash DiviVice President(Sales & Marketing,Logistics)-Mar 26
Mr. K. Subba RaoGeneral Manager(Human Resources)-Mar 26
Mr. D. Madhu BabuVice President(Projects)-Mar 26
Dr. L.V. RamanaVice President(Production)-Mar 26
Mr. L. Ramesh BabuVice President(Procurement)-Mar 26
Mr. S. RamakrishnaVice President(Production)-Mar 26
Mr. Y.T.S. PrasadHead(Global Quality)-Mar 26
Mr. M. Ramesh BabuChief Technologist-Mar 26
Dr. P. Srinivasa RaoChief Technologist-Mar 26
Mr. Venkatesa Perumallu PasumarthyChief Financial Officer-Mar 26

Divi's Laboratories Board of Directors

Divi's Laboratories Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Murali K DiviExecutive Director & MD10026Mar 26
N V RamanaExecutive Director5120Mar 26
Kiran S DiviExecutive Director / Whole Time Director / CEO3484Mar 26
Nilima Prasad DiviED / WTD - Commercial3478Mar 26
S. Devendra RaoExecutive Director / Whole Time Director326Mar 26
Ramesh B V NimmagaddaChairman & Independent Directo37Mar 26
S GanapatyIndependent Non Exe. Director34Mar 26
Kosaraju Veerayya ChowdaryIndependent Non Exe. Director33Mar 26
Sunaina SinghIndependent Non Exe. Director29Mar 26
Rajendrakumar Premchand ShahIndependent Non Exe. Director28Mar 26
Satish ChoudhuryCompany Sec. & Compli. Officer-Mar 26

Divi's Laboratories Brands

Brands owned by Divi's Laboratories

LOGOBRAND NAME
Divis Laboratories
Website: www.divislabs.com

About the company - Business Profile

Divi's Laboratories Ltd. is a leading Indian pharmaceutical company primarily engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical ingredients. It holds a significant global position as one of the top three API manufacturers and serves as a critical partner to 20 of the world’s top pharmaceutical innovators. The company operates through two main business segments: Generic APIs and Custom Synthesis of APIs and Intermediates for global innovator companies. With a strong focus on export markets, Divi's leverages its chemistry expertise and large-scale manufacturing capabilities to maintain a high degree of backward integration and supply chain reliability.

Key Points

  • Key Facts: Founded in 1990 and headquartered in Hyderabad, India, Divi's Laboratories is a publicly listed entity on the BSE and NSE. It specializes in large-scale manufacturing of generic APIs and custom synthesis for global innovators.
  • Operations and Resources: The company operates three major manufacturing facilities located at Choutuppal (Unit 1), Visakhapatnam (Unit 2), and Kakinada (Unit 3). Its total manufacturing capacity stands at 16,550 m³/KL. The company also maintains three R&D centers dedicated to process innovation.
  • Ownership: The company is promoter-led, with Dr. Murali K. Divi serving as the Managing Director. As of the latest reporting cycles, it remains an independent entity with no parent company.
  • Market and Significance: Divi's is a dominant player in the global API market, reaching over 100 countries. Approximately 88% to 90% of its revenue is derived from exports, with Europe and the United States contributing a combined 74% of sales.
  • Sustainability and Innovation: The company emphasizes "Green Chemistry" and sustainable business operations. Recent initiatives include the deployment of Solid Phase Peptide Synthesis (SPPS) and Liquid Phase Peptide Synthesis (LPPS) to target the expanding peptide API market (GLP-1, GLP-2, and GIP drugs).
  • Business Model: Divi's operates on a high-volume, low-cost model supported by deep backward integration. It excels in process chemistry, allowing for efficient production of complex molecules at a competitive scale.
  • Revenue Breakdown (FY2025):
    • Total Revenue: ₹9,198 crore (20% annual growth).
    • By Segment: Custom Synthesis (56%) and Generics (44%).
    • Nutraceuticals: Contributed ₹242 crore in the second quarter of FY2026.
    • By Geography (FY2024 data as per latest full regional split): Europe (52%), America (17%), India (13%), Asia (13%), and Rest of World (5%).
  • Key Products and Technology:
    • Portfolio: Over 160 products including Beta Carotene, Astaxanthin, Lycopene, and various vitamins (A, D3, D2, E Acetate).
    • Advanced Capabilities: Expansion into peptide synthesis and automated manufacturing processes.
  • Employee Trends: The company employs approximately 18,300 personnel.
  • Subsidiaries: Key subsidiaries include Divi's Laboratories (USA) Inc. and Divi's Laboratories Europe AG (Switzerland).
  • Strategic Initiatives: Current focus includes the Phase 1 expansion of Unit 3 at Kakinada to enhance capacity and backward integration. The company is also actively expanding its engagement across all clinical phases in custom synthesis.

References

  1. Annual Report May 2025
  2. Annual Report May 2024
  3. Earnings Transcript Feb 2026
  4. Earnings Transcript Nov 2025

Divi's Laboratories FAQ

Divi's Laboratories today is trading in the green, up by 1.2% at ₹9,780.
Divi's Laboratories is currently trading up 1.2% on an intraday basis. In the past week the stock rose 9.27%. Stock has been up 24.82% in the past quarter and rose 46.96% in the past year. You can view this in the share price history/seasonality section.
Divi's Laboratories is listed on NSE with the ticker DIVISLAB and on BSE as 532488. It's currently trading on NSE at a share price of ₹9,780 and on BSE with a share price of ₹9,715.
The market cap of Divi's Laboratories is ₹259,628.29 Cr. as of Oct 30, 2026.
Divi's Laboratories announced a FINAL dividend of 1500% which equals ₹30 in Jul 24, 2026.The last three ex-dates for Divi's Laboratories were Jul 25, 2025, Aug 02, 2024 and Aug 11, 2023. To view the full dividend history of Divi's Laboratories click here.
Divi's Laboratories has undergone 1 stock split and announced bonus shares 2 times since its BSE/NSE listing. The latest announcement for Divi's Laboratories stock split was on Aug 03, 2007 at a ratio of 10:2 and the last bonus share announcement was on Sep 23, 2015 at a ratio of 1:1.
Divi's Laboratories reported ₹3,144 Cr. in revenue, ₹902 Cr. in net profit, and ₹1,319 Cr. in EBITD as of Aug 01, 2026 for Q1 FY26-27.
According to the predictions of 29 analysts, the share price prediction for Divi's Laboratories is ₹8,612.17 with a downside of 12%.
The PE ratio of Divi's Laboratories is 88.76 as of Oct 30, 2026.
The PB ratio of Divi's Laboratories is 14.7 as of Oct 30, 2026.
You can view the latest analyst reports on the Divi's Laboratories reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×